Brenda Homony

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

Sharon Nachman, Naiyu Zheng, Edward P. Acosta et al. · Clinical Infectious Diseases · 2013 · 59 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

Sharon Nachman, C. Alvero, Edward P. Acosta et al. · Journal of the Pediatric Infectious Diseases Society · 2015 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

Pedro Cahn, Paul E. Sax, Kathleen Squires et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2018 · 25 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age

Matthew L. Rizk, Lihong Du, Chantelle Bennetto‐Hood et al. · The Journal of Clinical Pharmacology · 2015 · 17 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17